Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus

摘要

Objectives Defects in regulatory T cell (Treg) biology have been associated with human systemic autoimmune diseases, such as systemic lupus erythematosus (SLE). However, the origin of such Treg defects and their significance in the pathogenesis and treatment of SLE are still poorly understood.